Shares of cannabis giant Tilray Brands Inc (NASDAQ:TLRY) are trading higher Wednesday afternoon following breaking news of a potential major regulatory shift. Here’s what investors need to know.
- Tilray Brands shares are powering higher. What’s behind TLRY gains?
Why Easing DEA Barriers Is A Massive Catalyst For Tilray
Per a Wednesday Axios report, the Trump administration is expected to move to reclassify marijuana as soon as Wednesday, per an administration official familiar with the matter. The move follows an executive order from the president last year to reclassify marijuana as a Schedule III drug.
While it would not immediately legalize marijuana, it is a massive fundamental catalyst for Tilray. Reclassifying marijuana eases U.S. Drug Enforcement Administration barriers to researching the drug’s potential use cases.
This directly benefits Tilray as a company because the move would make it easier to study medicinal applications of marijuana. For a firm heavily invested in science-backed cannabis products, easing these federal limits removes critical operational bottlenecks.
Tilray can potentially accelerate its clinical research and aggressively expand its pipeline of medical treatments without facing historical DEA hurdles. Investors are likely bidding up the stock Wednesday as this rule change fuels optimism for the company’s future medical sector growth.
MACD Indicator Shows Strengthening Upside Momentum
Tilray is still working through a longer-term downtrend, but the current rebound is trying to rebuild a base after an April swing low. The stock is trading 13.9% above its 20-day simple moving average (SMA) and 6.3% below its 100-day SMA, which points to improving short-term traction but lingering intermediate resistance.
The moving average convergence divergence (MACD), a trend/momentum measure, is above its signal line and the histogram is positive, which leans toward strengthening upside momentum in the near term. In everyday terms, that MACD setup means recent price action is improving faster than the prior trend, even if the bigger picture is still mixed.
The bigger trend backdrop remains a headwind: the death cross in February (50-day SMA below the 200-day SMA) is consistent with sellers having controlled the longer-term tape. That's reinforced by the stock still sitting well below its 200-day SMA, a common "line in the sand" for longer-term trend followers.
- Key Resistance: $8.00 — a level where rallies have recently stalled.
- Key Support: $7.00 — an area where buyers have tended to step in.
TLRY Analyst Consensus: Buy Rating, $8.50 Price Target
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $8.50. Recent analyst moves include:
- Roth Capital: Upgraded to Buy (Maintains Target to $10.00) (April 2)
- TD Cowen: Buy (Lowers Target to $7.00) (March 30)
TLRY Shares Surge Wednesday Afternoon
TLRY Stock Price Activity: Tilray Brands shares were up 11.18% at $7.66 at the time of publication on Wednesday, according to Benzinga Pro data.
Image: Shutterstock
Login to comment